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Background: Tumour homing capacity of engineered human adipose-derived mesenchymal stromal cells
(ADMSCs) expressing anti-tumour agents might be the key for a much safer and yet efficient targeted tumour
therapy. However, ADMSCs exhibit resistant to most gene transfection techniques and the use of highly efficient
viral vectors has several disadvantages primarily concerning safety risk. Here, we optimized the use of highly
efficient and safe nucleofection-based transfection using plasmid encoded for TNF-Related Apoptosis Inducing
Ligand (TRAIL) into ADMSCs and investigated the potential anti-tumourigenic of TRAIL-expressing ADMSCs
(ADMSCs-TRAIL) on selected cancer models in vitro.
Methods: Different concentration of TRAIL-encoded plasmid and ADMSCs were nucleofected and the percentage
of fluorescence cells were analyzed to determine the optimal condition. TRAIL protein and mRNA were validated in
nucloeofected ADMSCs using ELISA and RT-PCR respectively. Evaluation of TRAIL specific death receptors were
performed on both tumours (A549/lung tumour, LN18/glioblastoma and HepG2/hepatocellular carcinoma) and
haematological malignant lines (REH/acute lymphocytic leukaemia, K562/chronic myelogenous leukaemia and
KMS-28BM/multiple myeloma) using flow cytometry. ADMSCs-TRAIL was subsequently assessed for anti-tumourigenic
properties using both proliferation assay (MTS assay) and apoptosis assay (Annexin-V / Propidium Iodide staining).
Results: Nucleofection showed increased total plasmid concentration (2 μg to 8 μg) resulted in significantly higher
reporter expression (11.33% to 39.7%) with slight reduction on cells viability (~10%). ADMSCs-TRAIL significantly
inhibited ~50% of cell proliferation in LN18, signifying sensitivity of the cell to ADMSCs-TRAIL mediated inhibition.
Inhibition of both tumour and malignant lines proliferation by ADMSCs-TRAIL conditioned medium noticed in HepG2,
A549 and REH respectively, whereas K562 and KMS-28BM malignant lines exhibit resistant to ADMSCs-TRAIL mediated
inhibition. Moreover, we found that native ADMSCs alone were capable of inducing apoptosis in both LN18 and HepG2
tumour lines, despite substantial increased on the percentage of apoptosis by ADMSCs-TRAIL.
Conclusion: ADMSCs-TRAIL selectively inhibit cancer model and markedly induces apoptosis. Through investigation of
the specific TRAIL death receptors expression, we saw that the receptors expression did influence the sensitivity of
some but not all cancer lines to TRAIL-mediated inhibition. This study provides further insight into the anti-tumourigenic
potential of ADMSCs-TRAIL on different cancer models.
Keywords: Human adipose derived mesenchymal stromal cells, Nucleofection, TNF-related apoptosis inducing ligand
(TRAIL), Cancer cell lines, Proliferation, Apoptosis* Correspondence: kamal@imr.gov.my
Stem Cell Laboratory, Haematology Unit, Cancer Research Centre, Institute
for Medical Research (IMR), 50588 Kuala Lumpur, Malaysia
© 2014 Fakiruddin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Fakiruddin et al. Cancer Cell International 2014, 14:122 Page 2 of 13
http://www.cancerci.com/content/14/1/122Background
Human adipose-derived mesenchymal stromal cells
(ADMSCs) are characterized as subset of cells that are
multipotent, capable of self-renewal, propagation and
differentiation into three mesenchyme lineages (osteo-
genesis, adipogenesis and chondrogenesis) in vitro [1].
Compared to other type of stromal cells, human ADMSCs
serve as an attractive candidate for regenerative therapy as
these cells are easily isolated, expanded and differentiated
to other type of mature cells under specific growth induc-
tion. The differentiation ability of ADMSCs has been
made not only to three mesenchyme lineages, but also
into other type of cells such as hepatocyte [2-4], neuron
[5-7] and insulin producing cells [7-10].
Homing characteristic of mesenchymal stromal cells
(MSCs) to the tumour microenvironment, suggested that
these cells might play a role during tumour development
[11-13]. Several studies that performed genetic alteration
of ADMSCs found that exogenous expression of thera-
peutic genes enhanced the treatment efficacy of ADMSCs
on the target site [14-17]. Ideally, by utilizing both engi-
neered ADMSCs and tumour homing characteristic of
these cells, an efficient site-specific tumour treatment can
be generated [18]. Like most primary cell lines, ADMSCs
exhibit resistant to classical gene transfection technique
and currently the most efficient gene delivery system is
through viral transduction. However, the use of virally
transduced cells for clinical application has been ham-
pered due to its potential mutation, immune response and
‘safeness’ [19].
The nucleofection technology is a safe non-viral
electroporation-based transfection system that combines
both specific electrical parameters and cell type transfec-
tion solutions to drive plasmid DNA, oligonucleotides and
siRNA directly to the cytoplasm and nucleus of the cell
[20]. Using this method, high transfection efficiency can
be achieved in hard to transfect cells [21]. This method
has been successful in primary cells such as neurons [22]
and keratinocytes [23]. Despite most studies that pre-
sented the method on primary cells, there are few reports
on the optimization technique specific on ADMSCs. Thus
we studied on the technique based on plasmid concentra-
tion, cell number and the exogenous gene expression.
To study the process of nucleofection optimization and
also the anti-tumourigenic effects of genetically engi-
neered ADMSCs expressing TRAIL (ADMSCs-TRAIL)
on both haematological malignancies and solid tumours,
we used the tumour necrosis factor (TNF)-related apop-
tosis inducing ligand (TRAIL) gene. It is a type II
membrane-bound (MB) protein that can be processed
by cysteine protease to generate soluble ligand. Both
MB protein and soluble ligand can rapidly induce
apoptosis in variety of cancers [24]. Although several
studies had shown the anti-tumour effect of exogenousTRAIL, systemic bioavailability and the toxicity of
the agent hindered the used of this ligand for fu-
ture clinical application [25]. Nonetheless, by utilizing
ADMSCs as a vehicle for stable TRAIL secretion
directly to the tumour microenvironment, efficacies of
TRAIL therapy can be enhanced and off target toxicity
evoke by non-specific TRAIL receptor binding may be
overcome.
In the present study, we performed optimization of
nucleofection (Amaxa™) based transfection to drive DNA
plasmid encoded for TRAIL into ADMSCs (ADMSCs-
TRAIL). Two DNA plasmid, pCMV6 (Origene Rockville,
MD) and pLOC (Thermo Scientific, Waltham, MA)
encoded for TRAIL was compared for reporter expression
in HEK293T cells and plasmid with the highest reporter
expression was selected for our subsequent analysis.
We report for the first time selective inhibition of
ADMSCs-TRAIL based on specific cancer type of both
haematological and non-haematological malignancies.
The objective of this study is to provide further under-
standing on the potential application of ADMSCs-TRAIL
based on different cancer models.
Results
Morphological characterization of ADMSCs in vitro
The ADMSCs at passage 2 were purchased from the
American Type Culture Collection (ATCC, Manassas,
USA), grown and expanded using defined ATCC media
specific for human mesenchymal stromal cells. The
morphology of these cells appeared to be fibroblastic,
elongated and spindle shape (Figure 1A). Apart from
slight reduction in the proliferation rate, the cells
could be expanded up to passage 6, with no apparent
morphological changes (Figure 1A). For this study,
cells below or at passage 6 were used for all of the ex-
periment. Karyotypic analysis performed at passage
3 and passage 6 showing cells are genomically stable
(Figure 1A).
Specific germ layer markers expression
Semi quantitative reverse transcriptase polymerase
chain reaction (RT-PCR) was performed for pluripotent
(Rex-1 and TDGF), ectodermal (Nestin and Sox-2) and
mesodermal (Bmp-4 and Gata-2) markers expression
between differentiated (adipogenic and osteogenic) to
non-differentiated ADMSCs. Results were presented
with higher pluripotent, ectodermal and mesodermal
markers in non-differentiated ADMSCs compared to
differentiated cells (Figure 1B).
Lineages differentiation of ADMSCs
The ADMSCs were induced into adipogenic and osteo-
genic using specific differentiation medium purchased










































Figure 1 Characterization of ADMSCs. Phase contrast of in vitro expanded ADMSCs at passage 3 and passage 6 showing both consistent with
fibroblast-like morphology (magnification: 10X) (A). Genomic stability was also observed in ADMSCs at passage 3 and passage 6 (A). Semi quantitative
RT-PCR analysis of germ specific markers in uninduced ADMSCs (P2) when compared to induced (adipogenic and osteogenic) ADMSCs;
template = 5ul, PCR cycle =30, internal control is GAPDH (B). Mesenchymal lineages differentiation of adipogenesis (C) stained with Oil Red O and
osteogenesis (D) stained with Alizarin Red were performed and results of RT-PCR for the relevant transcripts after differentiation were also depicted
(left lane: uninduced cells and right lane: induced cells).
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displayed by intracellular lipid accumulation and veri-
fied by Oil Red O staining (Figure 1C). The expression
of adipogenic specific transcripts such as leptin and
PPARγ was also positive as compared to uninduced cells
(Figure 1C). The osteogenic differentiation potential of
ADMSCs was confirmed by the calcium deposit charac-
teristic of bone formation detected by Alizarin Red
staining (Figure 1D). In addition, the induced cells
expressed osteogenic specific transcripts such as osteo-
calcin (OSC) and alkaline phosphatase (ALP) compared
to uninduced cells (Figure 1D).
Selection for an optimal expression vector
Both plasmid vectors, pCMV6 (Origene) and pLOC
(Thermo Scientific) either encoded for TRAIL [target
vector (TRAIL)] or vector alone [empty vector (EV)]
were transiently co-transfected into HEK293T cells
using Fugene6 (Roche) transfection reagents with 3:1transfection reagent to plasmid ratio, and incubated for
48 hours. Pictures taken from fluorescence optical mi-
croscopy revealed empty vector (EV) with high reporter
expression for both pCMV6 and pLOC plasmid, how-
ever, target vector (TRAIL) presented with lower re-
porter expression in pCMV6 compared to the pLOC
plasmid (Figure 2A-B). Fluorescence quantification on
the EV presented with significantly higher (p < 0.001)
fluorescence events in pLOC plasmid compared to
pCMV6 with 38.29% and 17.64% respectively (Figure 2C).
Similarly for the target vector (TRAIL), pLOC plasmid
presented with higher fluorescence events (p < 0.001)
with 25.09%, compared to pCMV6 plasmid with only
2.34% (Figure 2C). Subsequent quantitative RT-PCR
analysis validated the increased of TRAIL gene expres-
sion on HEK293T cells after pLOC plasmid transfection
(Figure 2D). Based on comparison of reporter expres-
sion between both vectors, pLOC plasmid was chosen
































Blast.tRFPCMV IRES 2a polyAsig.
Blast.tGFPCMV TRAIL IRES 2a polyAsig.
pCMV6-GFP [Empty Vector(EV)]
pCMV6-TRAIL-GFP [Target Vector (TRAIL)]
pLOC-RFP [Empty Vector(EV)]








































Figure 2 Selection for the optimal TRAIL expression vectors in HEK293T cells. HEK293T cells were transiently co-transfected with either
pCMV6 (A) or pLOC (B) plasmid using Fugene 6 (3:1 transfection reagent to DNA ratio) and images obtained by fluorescence inverted microscopy
(magnification: 10X). Significantly higher percentage of fluorescence cells after pLOC plasmid transfection compared to pCMV6 for both the
empty vector (EV) and TRAIL encoded plasmid as quantified by FACS, (C). Expression of TRAIL transcript was confirmed by quantitative RT-PCR
and GAPDH was used as internal control for the analysis (D). Plasmid map for the relevant vectors were also depicted (E; **p < 0.001; t-test).
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Figure 3 Nucleofection optimization and validation of TRAIL gene and protein expression in ADMSCs. Optimization was performed based
on different concentration of TRAIL encoded pLOC plasmid and cell number. Higher amount of the plasmid significantly increased percentage of
efficiency and yield, with reduction on cells viability (A). However, increased total number of cells with the highest plasmid concentration enhanced
cellular viability of the nucelofected ADMSCs (A). A substantially high level of TRAIL mRNA (B) and secreted protein expression (C) validated exogenous
TRAIL expression in nucleofected ADMSCs as analyzed by quantitative RT-PCR and ELISA respectively .
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expression in post-nucleofected ADMSCs
To further enhanced reporter expression in nucleofection-
based transfection, we increased the plasmid concentration
of the target vector (TRAIL). Initially, we used manufac-
turer (Amaxa) recommended protocol consisting of 2 μg
plasmid and 5.0 x 105 total cells in a single reaction. How-
ever, due to the low reporter expression as quantified by
FACS, we increased the plasmid concentration from 2 μg
up to 8 μg in a single reaction while maintaining the
same number of cells per reaction, and 2 μg of pMAX-
GFP plasmid was used as control. As expected, in-
creased plasmid concentration of 8 μg, we managed to
achieve higher percentage of events (p < 0.001) resulting
in up to 25.49% efficiency and 37.82% yield compared to
11.70% efficiency and 14.67% yield using manufacturer
recommended protocol (Figure 3A).
Increased cell number reduced toxic effects caused by
high plasmid concentration
We noticed that even though reporter expression en-
hanced as plasmid concentration increased, percentage
of viability reduced to 67.21% when cells were trans-
fected with the highest plasmid concentration (8 μg per
reaction) compared to 87.50% viability when 2 μg of
plasmid concentration was used as recommended by the
manufacturer (Figure 3A). Thus, we next tested whether
percentage of viability, yield and efficiency can be en-
hanced with higher number of cells. Hence, 10 μg of
pLOC plasmid encoded for TRAIL with increased number
of cells for up to 3.0 x 106 were used for each reaction.
Surprisingly, when nucleofection was performed with the
highest number of cells (3.0 x 106 cells per reaction), we
observed the percentage of viability enhanced to 81.16%,
with percentage of efficiency and yield increased to
39.80% and 49.00% respectively which is ~10% higher
compared to the previous analysis (Figure 3A).
TRAIL-expressing ADMSCs validated by mRNA and
protein analysis
Validation of TRAIL gene and protein expression in
post-nucleofected ADMSCs was performed using quan-
titative RT-PCR and ELISA respectively. Substantial in-
creased (p < 0.001) in fold change for TRAIL gene
expression between ADMSCs nucleofected with plasmid
encoded for TRAIL compared to the empty vector was
noticed (Figure 3B). Significantly high (p < 0.001) TRAILprotein was detected between 48 hours to 72 hours in
conditioned medium of ADMSCs after pLOC TRAIL
nucleofection confirming that the TRAIL protein retained
as a secreted ligand between indicated time point for
in vitro analysis (Figure 3C).
High percentage of the TRAIL ligand needed to exert
anti-proliferative effects in selected haematological
malignant line
Inhibition of cell proliferation from 100% (basal) to 76%
and 61% was noticed in REH line cultured with 80% and
100% ADMSCs-TRAIL conditioned medium (Figure 4B).
This result is consistent with the high R2 (DR5) TRAIL
receptor expression seen in REH line (Figure 4A). How-
ever, high concentration of ADMSCs-TRAIL condi-
tioned medium is needed to induce meaningful effects.
In contrast KMS-28BM and K562 lines showed resist-
ance to TRAIL ligand when cells were cultured with
ADMSCs-TRAIL conditioned medium (Figure 4B).
ADMSCs-TRAIL enhanced specific haematological
malignant growth
In contrast to the inhibitory effects induced by ADMSC-
TRAIL conditioned medium on REH malignant line,
direct co-culture with ADMSCs-TRAIL did not induce
significant inhibition as shown by Figure 4C. Further-
more, direct co-culture of both REH and KMS-28BM
malignant lines with increased number of ADMSCs-
TRAIL significantly enhanced their proliferation. K562
showed no changes on its proliferation as the cell were
cultured with increased number of ADMSCs-TRAIL.
Specific tumour lines inhibition by ADMSCs-TRAIL
We further evaluated the anti-proliferative effect of
ADMSCs-TRAIL and its conditioned medium on se-
lected panel of solid tumour lines. Our result indicates
consistent tumour inhibition from 100% cell prolifera-
tion to 75%, 67% and 48%, noticed in LN18 cultured
with 40%, 60% and 100% ADMSCs-TRAIL conditioned
medium respectively (Figure 5B). Persistent inhibition of
LN18 proliferation was also noticed when the tumour
cell cultured with increased ratio of ADMSCs-TRAIL as
shown by Figure 5C, suggesting LN18 is highly sensitive
to TRAIL-mediated inhibition. High percentage of con-
ditioned medium (80% - 100%) was needed to exert
anti-proliferative effects in both A549 and HepG2 as
shown by Figure 5B with no apparent changes on
AB
C
Figure 4 The anti-proliferative effects of ADMSCs-TRAIL on
haematological malignancies as analyzed by MTS assay. FACS
analysis of TRAIL receptors revealed that only R2 (DR5) expression
was high in both K562 and REH lines, whereas lower expression of
all four receptors was seen in KMS-28BM (A). ADMSCs-TRAIL and its
conditioned medium (80% and 100% ) induced significant inhibition
of REH proliferation, whereas both K562 and KMS-28BM remained
resistant to TRAIL-mediated inhibition (B). Increased ratio of
ADMSCs-TRAIL and malignant lines induced significant cellular
proliferation noticed in REH and KMS-28BM (C; *p < 0.01,
**p < 0.001; t-test).
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number of ADMSCs-TRAIL (Figure 5C).
TRAIL secretion by ADMSCs enhanced tumour apoptosis
induced by native ADMSCs
Direct co-culture using transwell assay was performed to
further validate the induction of apoptosis by TRAILsecreting ADMSCs. Induction of apoptosis was no-
ticed on both LN18 and HepG2 cultured with the na-
tive ADMSCs with 13.41% and 10.60% respectively
(Figure 5D). Moreover, the apoptotic effect was sig-
nificantly enhanced to 18.32% and 17.65% for both
LN18 and HepG2 respectively when these cells were
cultured with ADMSCs-TRAIL (Figure 5D). The per-
centage of apoptosis was slightly increased when A549
line was cultured with the ADMSCs-TRAIL as com-
pared to native ADMSCs (Figure 5D).
Discussion
The tumour homing capacities of MSCs have led to the
profound idea of developing genetically engineered
ADMSCs expressing anti-tumour agents as a cell based
vector system. This on site specific targeted therapy may
later be applied in patients to enhance treatment efficacy
and reduce systemic toxicity [26]. However, to produced
genetically engineered ADMSCs expressing death ligand
is a challenge, and like most primary cells, ADMSCs re-
main resistance to genetic alteration. In this study, we
report optimization of the nucleofection-based transfec-
tion using TRAIL gene on ADMSCs and evaluated the
anti-tumourigenic effects of TRAIL-expressing ADMSCs
on both haematological and non haematological malig-
nant lines. ADMSCs were characterized and validated
based on cellular morphology, genomic stability, germ
layers mRNA expression and mesenchymal lineages dif-
ferentiation (Figure 1). pLOC was selected over pCMV6
plasmid vector for subsequent transfection analysis on
ADMSCs based on the high level of reporter expression
observed in HEK293T (Figure 2). We believe that the
IRES (internal ribosome entry site) sequence, which is
part of the pLOC plasmid DNA, might enhance trans-
gene expression in HEK293T cells as shown by Figure 2E
[27]. We performed optimization of nucleofection-based
transfection using different concentration of TRAIL
encoded pLOC plasmid with increased ADMSCs cell
number per reaction. Higher plasmid concentration of
8 μg increased the reporter expression up to 2 fold with
moderate reduction on cell viability (Figure 3A). How-
ever, we manage to substantially enhanced cell viability
when total number of cells was increased to 3.0 x 106
cells per reaction and this directly improved efficiency of
the reporter expression and yield (Figure 3A). This ob-
servation suggested that higher number of cells may re-
duce toxicity effect induced by the plasmid. In addition,
we also verified the mRNA and protein expression of
TRAIL in nucleofected ADMSCs using quantitative RT-
PCR and ELISA respectively (Figure 3B-C).
Binding of the TRAIL ligand to the intracellular region
of R1 (DR4) and R2 (DR5) receptors leads to the recruit-
ment of death-inducing signalling complex (DISC) and
the activation of the death signal by apoptosis [28]. In
A C
  DB
Figure 5 ADMSCs-TRAIL inhibited proliferation and induced tumour cell apoptosis. High R2 (DR5) and R4 (DcR2) TRAIL receptors
expression was noticed in A549, LN18 and HepG2 lines (A). Proliferation of LN18 was persistently inhibited as the tumour line was cultured with
40% to 100% ADMSCs-TRAIL conditioned medium. However, the inhibition of A549 and HepG2 tumour lines was only noticed when the cells
were cultured with 80% and 100% ADMSCs-TRAIL conditioned medium (B). Constant inhibition of LN18 tumour lines noticed when cultured with
increased number of ADMSCs-TRAIL (C). Native ADMSCs alone were able to induce apoptosis in both LN18 and HepG2; in addition, the apoptotic
effect was enhanced when the tumour cells were cultured with ADMSCs-TRAIL (D; *p < 0.01, **p < 0.001; t-test).
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will compete for the binding of the TRAIL ligand to the
R1 and R2 receptors, resulted in blocking of TRAIL-
mediated apoptosis and leading to insensitivity of the
TRAIL therapy to the tumour [28]. Study on the anti-
tumourigenic effects of secreted TRAIL ligand by
ADMSCs-TRAIL on haematological malignancy corre-
lated to the R2 (DR5) receptor expression as shown by
KMS-28BM and REH lines. Lowest R2 (DR5) receptor
expression in KMS-24BM may have caused the cells re-
sistant to TRAIL-mediated inhibition (Figure 4B). In con-
trast, high expression of the R2 (DR5) receptor expression
in REH caused the cells sensitive to TRAIL-mediated
inhibition when the cells were cultured with the highest
percentage of ADMSCs-TRAIL conditioned medium
(Figure 4B). However, the presence of R2 (DR5) may
not necessarily correlate to the sensitivity of the malig-
nant cells to TRAIL as shown in K562 lines (Figure 4A),
indicating some cells may have high expression ofapoptotic resistance genes or low expression of caspases
mediated cell death that circumvent TRAIL-mediated
apoptosis [29]. High expression of the R3 (DcR1) and R4
(DcR2) seen in K562 cell line compared to other haema-
tological malignant lines may also contribute to the re-
sistance phenotype of this cells to TRAIL-mediated
inhibition (Figure 4A).
MSCs are known for its ability as immune modulator
capable of regulating proliferation and differentiation of
immune cells such as macrophages, B and T cells, NK
cells, and even mast cells [30]. Studies suggested that
MSCs promote cellular proliferation and maintenance of
either normal or malignant hematopoietic cells in direct
co-culture [31,32]. Our results indicated TRAIL secretion
by ADMSCs induced cellular inhibition of hematopoietic
malignant cell noticed in REH line shown by Figure 4B.
However, direct cell to cell contact between ADMSCs-
TRAIL and leukemic lines namely REH and KMS-28BM
may circumvent the inhibitory effects induced by secreted
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promote hematopoietic malignant survival. Therefore, we
believed precautions should be taken if ADMSCs express-
ing anti-tumour ligand is to be applied in the context of
haematological malignancies.
Consistent tumour inhibition and apoptosis seen in
LN18 cultured with ADMSCs-TRAIL and its condi-
tioned medium signifying that the cell is highly sensitive
to TRAIL-mediated inhibition (Figure 5B-D). Further-
more, as indicated in Figure 5D, significantly high induc-
tion of apoptosis by native ADMSCs co-cultured directly
with both LN18 and HepG2 was observed, while
TRAIL-secreting ADMSCs substantially induced higher
percentage of apoptosis on both lines. These results
might be due to the secreted factors (cytokines and che-
mokines) by MSCs that influence the anti-tumourigenic
effects in several cancer models [33]. Correlated to the
high R2 (DR5) receptor expression and also the high
percentage of apoptosis noticed in HepG2 tumour line,
this cell may appear to be highly sensitivity to ADMSCs-
TRAIL mediated inhibition. However, there is no appar-
ent change on HepG2 tumour cells proliferation
when these cells were cultured with ADMSCs-TRAIL
(Figure 5C). This result suggested that ADMSCs-TRAIL
does induced cytotoxicity by binding of the TRAIL
ligand secreted by ADMSCs-TRAIL to the R2 (DR5) re-
ceptor on HepG2 as analyzed by the apoptosis assay
(Figure 5D). However it may not necessarily induced
cytostaticity to the proliferation of HepG2 cells, as the
cells may still be highly proliferative and resistance to
TRAIL-mediated inhibition. HepG2 tumour line has been
known for its resistance phenotype to TRAIL-mediated
inhibition as reported by several papers [34-36]. In fact,
there are also few papers that shown apoptosis may not
certainly effect cellular proliferation as these two processes
are independent to each other [37,38]. High expression of
the R2 (DR4) receptor as seen in A549 theoretically
indicated that this cells are highly sensitive to TRAIL-
mediated apoptosis (Figure 5A). However, our results
showed that the anti-proliferation effect of TRAIL ligand
is only exerted as the cells were cultured with high con-
centration of ADMSCs-TRAIL conditioned medium
(Figure 5B). Moreover, slight reduction of A549 prolifera-
tion was noticed when the cell was cultured with in-
creased number of ADMSCs-TRAIL with no apparent
proliferative inhibition (Figure 5C). We believed that this
is due to the competitive binding of the TRAIL ligand to
R1 and R2 receptors by high expression of both R3
(DcR1) and R4 (DcR2) receptor that reduced TRAIL-
mediated apoptosis in A549 shown by Figure 5A.
In summary, our data demonstrated that nucleofection
is efficient to deliver TRAIL gene into ADMSCs. How-
ever, suitable plasmid design, optimal plasmid concen-
tration and cell number are needed to achieve an idealcondition for the technique. We believe that the R2
(DR5) receptor expression does not inevitably signify the
sensitivity of the malignant cells to TRAIL-mediated
apoptosis as observed in K562, A549 and HepG2 cell
lines model. Moreover, the properties of native ADMSCs
do play an essential role in the induction of anti-
tumourigenic effect and TRAIL secretion by ADMSCs-
TRAIL may enhance ADMSCs-mediated tumour
inhibition as noticed in both LN18 and HepG2 lines. In
the framework of haematological malignancies, due to
the contradicting effect of ADMSCs-TRAIL and its con-
ditioned medium, we believed therapeutic exploitation
of ADMSCs-TRAIL in the context of haematological
malignancies would not be suitable as it may enhance
the survival of haematological malignant cells. Finally,
we concluded that more functional assessments are still
needed if anti-tumour targeted strategy utilizing ADMSCs-
TRAIL is to be developed in the near future.
Materials and methods
The research protocol was approved by our institutional
review boards (Medical Research Ethics Committee/
MREC, Ministry of Health Malaysia).
Cell lines
The human adipose-derived mesenchymal stromal cells
(ADMSCs) at passage 2 were purchased from the
American Type Culture Collection (ATCC, Manassas,
USA) and HEK293T was courtesy of Dr Alan Khoo Soo
Beng (Molecular Pathology Unit, Institute for Medical
Research, Malaysia). Solid tumour lines [A549 (lung
tumour), LN18 (glioblastoma) and HepG2 (hepatocellular
carcinoma)] were purchased from ATCC. Non-adherent
hematopoietic malignant lines [REH (acute lymphocytic
leukaemia), K562 (chronic myelogenous leukaemia)] and
KMS-28BM (multiple myeloma) were purchased from
ATCC and JCRB cell bank respectively.
Cell culture
The ADMSCs were cultured in specific MSCs growth
medium purchased from ATCC, supplemented with 2%
fetal bovine serum (FBS), 5 ng/mL recombinant basic
fibroblast growth factor (rh FGF), 5 ng/mL rh FGF
acidic, 5 ng/mL recombinant epidermal growth factor
(rh EGF), 10 μg/mL gentamicin, 0.25 μg/mL amphoteri-
cin B, 10 Units/mL penicillin and 33 μM phenol red, (all
purchased from ATCC, Manassas, USA). Eight percent
of fetal bovine serum (ATCC) was added later into the
complete medium to make 10 serum concentration as
complete working medium. The cells were incubated in
a humidified incubator at 37°C supplied with 5% carbon
dioxide, routinely maintained in 75 cm2 tissue culture
flasks and harvested when cells reached 80-90%
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culturing and expansion.
The HEK293T cells were cultured in DMEM high glu-
cose with sodium pyruvate supplemented with 10% FBS
and 100 IU/ml penicillin, 100 μg/ml streptomycin (all
from Invitrogen Corporation, Carlsbad, CA). The cultures
were maintained in 5% CO2 in a humidified incubator at
37°C. When the cells reached 80%–90% confluence, the
cells were harvested with 0.25% trypsin-EDTA (Invitrogen
Corporation) and subcultured for expansion.
Cancer lines (A549, LN18, HepG2, REH, K562 and
KMS-28BM) were cultured in RPMI-1640 supplemented
with 10% FBS and 100 IU/ml penicillin, 100 μg/ml
streptomycin, 1% non essential amino acids (NEAA) and
1% L-Glutamine (all from Invitrogen Corporation, Carls-
bad, CA). The cultures were maintained in 5% CO2 in a
humidified incubator at 37°C. When adherent tumour
cells reached 80%–90% confluence, cells were harvested
with 0.25% trypsin-EDTA (Invitrogen Corporation) and
subcultured for expansion.
Karyotyping analysis
Genomic stability of ADMSCs in passage 3 and passage
6 was investigated using the conventional karyotyping,
and analyzed using the standard G-banding technique.
Metaphase spreads were prepared using standard pro-
cedure of 10 μg/ml colcemide treatment for 4 hours,
followed by 0.075 M potassium chloride hypotonic treat-
ment and methanol/glacial acetic acid fixation (3:1) ra-
tio. GTG-banding using TrypLE™ Express (Gibco by Life
Technologies, Grand Island, NY, USA) pre-treatment
was performed according to established protocol. Cyto-
genetic analysis was performed using Cytovision 7.3 soft-
ware. Microscopy was performed using optical bright
field, Olympus BX 50. Ten G-banded metaphases were
analyzed for each sample.
Reverse transcription polymerase chain reaction (RT– PCR)
analysis
Expression of pluripotent (Rex-1 and TDGF) and germ
layer specific (BMP-4, GATA-2, Nestin and SOX-2)
markers were evaluated between non-differentiated
ADMSCs at passage 2 and differentiated (adipogenic
and osteogenic) cells. To validate differentiation of
ADMSCs into specific lineages, expression of genes re-
lated to adipogenic (Leptin and PPARγ) and osteogenic
(osteocalcin and ALP) was performed. Total RNA was
extracted using RNAeasy kit (Qiagen Hamburg GmbH,
Germany) according to the manufacturer’s protocol.
The extracted RNA was quantified at 260 nm absorbance,
and purity of RNA was evaluated from the 260/280-
absorbance ratio using the spectrophotometer (BioPho-
tometer Plus, Eppendorf, Hamburg, Germany). First
strand cDNA was synthesized using the Transcriptor FirstStrand cDNA synthesis kit (Roche Applied Science, Non-
nenwald, Penzberg, Germany) according to manufacturer
protocol. PCR were performed with primers (Table 1) and
PCR kit (Promega, Madison, WI, USA) on a thermocycler
(Eppendoff Mastercycler gradient, Hamburg, Germany).
Initial denaturation was performed at 94°C for 5 min,
followed by denaturation at 94°C for 30 s, annealing at
55°C for 30 s, and extension at 72°C for 1 min for 30 cycles.
A final extension of 10 min at 72°C was also performed
for each reaction. The PCR products were analyzed on
1.2% FlashGel™ agarose electrophoresis system (Cambrex,
USA). GAPDH was used as an internal control.
Quantitative reverse transcription polymerase chain
reaction (qRT– PCR)
Quantitative gene expression of TRAIL was evaluated in
both HEK293T and ADMSCs after plasmid transfection
and nucleofection respectively. Initially, total RNA was
extracted and evaluated for purity as previously de-
scribed. First strand cDNA was synthesized using the
Transcriptor First Strand cDNA synthesis kit (Roche
Applied Science, Nonnenwald, Penzberg, Germany) ac-
cording to manufacturer protocol. The qRT-PCR reac-
tion was prepared using SYBR 1 master mix (Roche
Applied Science, Nonnenwald, Penzberg, Germany) and
primers as stated (Table 1). Quantitative RT-PCR was
performed using the lightcycler 480 (Roche) under the
following cycle conditions; Pre-denaturation for 4 mins
at 95°C followed by 40 cycles consisting of denaturation
at 95°C for 15 sec, annealing at 60°C for 30 sec and ex-
tension at 72°C for 30 sec followed by dissociation curve.
The basic relative gene expression (RQ) was calculated
manually (refer below) and the efficiency (E) of primer
binding equal to 2.
Relative expression RQð Þ
¼ ETarget
ΔCp Target Mean Cp Control – Mean Cp Sampleð Þ
EReferenceΔCp Reference Mean Cp Control – Mean Cp Sampleð Þ
Target: Target genes analyzed (TRAIL)
Reference: Reference Genes (GAPDH)
Sample: HEK293T and/or ADMSCs (Transfected with
pLOC-TRAIL encoded plasmid)
Control: HEK293T and/or ADMSCs [Transfected with
pLOC-EV (Empty Vector) plasmid]
Adipogenic and osteogenic differentiation
The ADMSCs were induced for adipogenic and osteo-
genic differentiation using specific lineage differentiation
medium (ATCC, Manassas, USA). Passage 3 ADMSCs
were seeded at 1.7 × 105 cells/well in 6 wells tissue cul-
ture plates (BD) for 24 hours. The next day, medium
Table 1 Human primer sequences used for RT-PCR
Gene Accession Sense primer Antisense primer Product Size (bp)
Nestin NM_006617.1 CAGCGTTGGAACAGAGGTTGG TGGCACAGGTGTCTCAAGGGTAG 389
BMP 4 NM_130851.2 GTCCTGCTAGGAGGCGCGAG GTTCTCCAGATGTTCTTCG 338
Rex-1 NM_174900 GCGTACGCAAATTAAAGTCCAGA ATCCTAAACCAGCTCGCAGAAT 282
Gata-2 NM_001145661.1 AGCCGGCACCTGTTGTGCAA TGACTTCTCCTGCATGCACT 243
TDGF NM_003212.3 GCCCGCTTCTCTTACAGTGTGATT AGTACGTGCAGACGGTGGTAGTTCT 497
Sox 2 NM_003106.3 CCCCCGGCGGCAATAGCA TCGGCGCCGGGGAGATACAT 447
Leptin NM_000230.2 TGTGCCCATCCAAAAAGTCC GTTTGGAGGAGACTGACTGCG 100
PPARγ NM_015869.4 GAGCACTTCACAAGAAATTACC AATGCTGGAGAAATCAACTG 151
ALP NM_000478.4 GGAAGGGTCAGTCAGGTT GTGGGCCGCTCTAGGCACCAA 500
Osteocalcin NM_199173.4 ATGAGAGCCCTCACACTCCTC GCCGTAGAAGCGCCGATAGGC 294
TRAIL NM_003810.2 TTGTTGATGAAAAGTGCTAGAAATA ATGGTCCATGTCTATCAAGTGC 150
GAPDH NM_002046.4 TGAAGGTCGGAGTCAACGGATT CATGTGGGCCATGAGGTCCACCAC 530
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ferentiation medium. Cells were induced for 21 days with
medium being changed once every alternate day. After
21 days, the adipogenic and osteogenic cultures were fixed
and stained with Oil Red O (0.3%) and Alizarin Red solu-
tion respectively. The stained cells were examined under
an inverted microscope immediately after staining. Expres-
sion of adipogenesis (leptin and PPARγ) and osteogenesis
(osteocalcin and ALP) markers was also assessed using
RT–PCR.
Plasmids construct
Plasmid vectors (pCMV6 and pLOC) either with or
without the TRAIL coding sequence were purchased
from Origene (Rockville, USA) and Thermo Scientific
(Waltham, MA) respectively. For the empty vector (EV),
both pCMV6 and pLOC were tagged either with green
fluorescence protein (GFP) and red fluorescence protein
(RFP) respectively, whereas for the TRAIL encoded plas-
mids, both pLOC and pCMV6 consisted of only GFP tag
protein. Both plasmids utilized cytomegalovirus (CMV)
immediate early promoter to drive transgene expression.
pCMV6 plasmid vector consist of C-terminal for mam-
malian protein expression, while pLOC plasmid consist
of the IRES (internal ribosome entry site) sequence for
simultaneous expression of both transgene and fluores-
cence tag proteins.
HEK293T transfection
Transfection using the lipid-based system namely
Fugene6 (Roche) in HEK293T using both pCMV6 and
pLOC plasmid was performed following procedures rec-
ommended by manufacturer. In brief, cells were seeded
in six-well plates at a density of 5.0 × 105 cells per well
and allowed to grow overnight. Transfection complex,
consisting of 2 μg of plasmid and 6 μl of transfection re-
agents, was directly added to the wells in the presence ofserum-containing medium, and cells were assayed 48 hours
later for reporter expression using flow cytometry.
ADMSCs nucleofection
The Nucleofection of ADMSCs was performed accor-
ding to the manufacture recommendation (Amaxa Bio-
system, Cologne, Germany) and pMAX-GFP plasmid
was used as control. Briefly, different cell number and
plasmid concentration of the TRAIL encoded pLOC
plasmid were suspended in 100 μl of human mesenchy-
mal nucleofection solution (Amaxa Biosystem), and
pulsed with U23 (high efficiency) program. Immediately
after nucleofection, cells were transferred into pre-
warmed fresh complete medium in six-well plates and
left to grow overnight. The next day, medium was dis-
carded and cells were washed few times to remove deb-
ris. Cells were left to grow for another 48 hours before
medium was harvested and stored at −80°C for further
downstream application. Cells were subjected to fluor-
escence activated cell sorting (FACS) 72 hours post-
nucleofection.
Analysis of transfection efficiency, viability and yield
Analysis of fluorescence cells in both HEK293T and
ADMSCs-TRAIL was performed using flow cytometry.
Briefly, cells were detached from 6 wells plate by 5 mi-
nute 0.25% trypsin-EDTA incubation, recovered by cen-
trifugation and washed in PBS containing 2% FBS. FACS
Calibur instrument (Becton Dickinson BD) was performed
and a total of 10,000 events were acquired for data analysis
by using Cell Quest software (BD, San Jose, CA). Non-
specific fluorescence was determined using wild type
(non-transfected) cells. Percentage of efficiency (GFP+)
was calculated based on the total percentage events
gated on the FL-1 channel. Viability of cells post transfec-
tion was assessed using propidium iodides (PI) staining
and evaluation was based on (GFP+/PI−) and (GFP−/PI−)
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was calculated based on the events gated on (GFP+/PI−)
area and compared to plated number of cells. Fluores-
cence cells was observed at 20× magnification using
CKX31 (Olympus, USA) inverted microscope.
Enzyme-linked immunosorbent assay (ELISA)
To assess the production of TRAIL secreted protein in
ADMSCs-TRAIL, supernatants and cell lysis were col-
lected at different times after nucleofection and assayed
in duplicates for TRAIL concentration using ELISA kit
(R&D Systems Inc., Minneapolis) according to manufac-
turer’s instruction.
Proliferation assay/MTS assay
The MTS assay [3-(4,5-dimethylthiazol-2-yl)-2H-tetrazo-
lium, inner salt] purchased from Promega was used to
evaluate the growth inhibitory effects of ADMSCs-
TRAIL and its conditioned medium on haematological
malignant and solid tumour lines by direct co-culture
system. During the execution of the experiments, all of
the cells (ADMSCs-TRAIL and cancer lines) were grown
in MSCs complete medium for culture standardization.
Briefly, 50 μl of cancer lines were seeded in 96 wells plate
(Corning Inc, Manassas, VA) at a density of 1.0 × 104
cells/well in 100 μl and left to grown overnight. Either in-
creased number of ADMSCs-TRAIL (20, 100, 500, 2000
total cells/50 μl fresh MSCs medium) based on ratio or
50 μl of different percentage ADMSCs-TRAIL condi-
tioned medium (20%-100%) was added into the wells and
incubated for 48 hours. Four hours before the end of the
experiment, 20 μl of MTS solution was added into each
well and the absorbance at 490 nm was measured using
Odyssey® SA Imaging System (Li-Cor, Lincoln, USA),
using wells without cells as blank. Proliferation of cancer
lines was calculated as follows: Cell Proliferation (% of
control) = (OD490 of stimulated malignant cells/OD490 of
unstimulated malignant cells) × 100%.
Apoptosis assay (annexin v and propidium iodide/PI)
staining
Apoptotic induction of ADMSCs-TRAIL on solid tumour
lines was performed using the annexin v/pi double stain-
ing kit purchased from (Becton Dickinson BD). For the
analysis, direct co-cultured between both ADMSCs-
TRAIL and tumour cells were performed using 24 wells
plate, 0.4 μm transwell system for physical separation of
both tumours and ADMSCs-TRAIL (SPL Life Sciences).
Briefly, 1.0 × 105 cells/well of ADMSCs-TRAIL and
ADMSCs were seeded on the insert and the same
number of tumours lines (1.0 × 105 cells/well) were seeded
on the bottom wells and co-cultured directly. 48 hours
later, tumour cells was harvested by trysinization and col-
lected by centrifugation. Cell palette was suspended in100 μl of 1× annexin v binding buffer (Becton Dickinson
BD) and 5 μl of annexin-v-FITC was added. Antibody in-
cubation was performed at 4°C for 20 minutes and 1 μl of
PI was later added before FACS aquisition. Stained cells
were subjected to flow cytometric analysis using FACS
Calibur instrument (Becton Dickinson BD) and a total of
10,000 events were acquired and analyzed using Cell
Quest software (Becton Dickinson BD).
Statistical analysis
Results are expressed as means ± SD (standard deviation)
of three independent experiments. Statistical analysis
was performed using the IBM SPSS statistic, version 21.
Comparison between two groups was performed using
the two-tailed t-test with P values of <0.01 were consi-
dered statistically significant. Comparison between groups
were performed using one factor analysis of variance
(ANOVA) followed by the Tukey’s post hoc.
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